HEALTHJun 17 · 03:00 UTCPOLITICO EUROPEChristophe Bourdon, CEO, LEO Pharma; board member, European Federation of Pharmaceutical Industries and Associations (EFPIA)

Do we want to lead or lag in life sciences?

Europe risks losing its leadership in the pharmaceutical sector due to geopolitical challenges and internal indifference, with the United States' Most-Favored-Nation pricing policy and China's rapid advancements in biotechnology and innovation exacerbating the decline. Europe lags behind in clinical trials, R&D spending, and attracting investment compared to the US and China.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

EuropeplaceUnited StatesplaceChinaplaceLeo PharmaorganizationChristophe BourdonpersonEFPIAorganizationpharmaceutical industrytopicbiotechnologytopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHMay 15 · 13:29 UTC
STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more
BUSINESSMay 12 · 08:30 UTC
Opinion: STAT+: Pharma and biotech leaders are destroying their own industry
BUSINESSJun 10 · 14:31 UTC
STAT+: Hope for Kendall Square’s lab market
HEALTH
Japan risks losing out without drug pricing reform, warns AstraZeneca CEO
TECHNOLOGYJun 2 · 11:00 UTC
The next tech war? Why biotech may become a new US-China battleground